Could a lower dose of blood cancer drugs be just as effective?

NCT ID NCT07474961

Not yet recruiting Disease control Sponsor: Anne Louise Tølbøll Sørensen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is for adults with multiple myeloma or Waldenstrom macroglobulinaemia. It tests whether giving certain drugs less often can control the disease as well as the standard schedule. The goal is to find the best balance between effectiveness and quality of life. About 400 people will take part across multiple hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teclistamab, talquetamab, elranatamab, linvoseltamab, ibrutinib, zanubrutinib
What this could lead to: If successful, this could show that less frequent dosing of these drugs controls blood cancers just as well, reducing side effects and treatment burden.
What could go wrong: This is a Phase 4 trial that hasn't started recruiting yet. It's testing dose changes, not a new cure, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA WALDENSTROM MACROGLOBULINAEMIA

Contacts and locations

Locations

Aalborg University Hospital

Aalborg, 9000, Denmark
Aarhus University Hospital

Aarhus, 8200, Denmark
Copenhagen University Hospital - Rigshospitalet

Copenhagen, Greater Copenhagen Area, 2100, Denmark
Odense University Hospital

Odense, 5000, Denmark
Roskilde University Hospital

Roskilde, 4000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.